Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR) Amid 'Bold Strategy'
Tweet Send to a Friend
Stifel analyst Bradley Canino reiterated a Buy rating and $56.00 price target on Kymera Therapeutics (NASDAQ: KYMR).The analyst said: "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
